மெட்டாஸ்டேடிக் ப்ராஸ்டேட் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Abiraterone Also Ups Survival in Nonmetastatic Prostate Cancer
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
The VISION Trial: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Kanibalismus, splývání a sebepojídání: Čeští vědci odhalili obranné strategie nádorů
nedd.tiscali.cz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nedd.tiscali.cz Daily Mail and Mail on Sunday newspapers.
Propella Therapeutics Inc. (Propella), a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Under the IND, Propella plans to initiate an open-label, phase 1/2a clinical study in June 2021. The phase 1 portion will have a dose-escalation design that will assess the safety, tolerability, pharmacokinetics, and preliminary clinical activity of PRL-02 in patients with metastatic prostate cancer.
email article
Men with poor-prognosis metastatic castration-resistant prostate cancer (mCRPC) had better outcomes with cabazitaxel (Cabometyx) as initial therapy instead of an androgen-receptor inhibitor, a phase II randomized trial showed.
First-line taxane therapy led to a clinical benefit rate (CBR, response plus stable disease) of 80% as compared with 62% for patients treated with either enzalutamide (Xtandi) or abiraterone (Zytiga). Patients treated with cabazitaxel lived more than twice as long, although the difference did not reach statistical significance because of a small patient population.
Patients treated with cabazitaxel had higher rates of grade ≥3 neutropenia, diarrhea, and infection, reported Kim N. Chi, MD, of BC Cancer in Vancouver, and colleagues, in